ReportWire

Tag: GILD

  • Nations Financial Group Inc. IA ADV Acquires 2,068 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

    Nations Financial Group Inc. IA ADV Acquires 2,068 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

    [ad_1]

    Nations Financial Group Inc. IA ADV lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 60.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,501 shares of the biopharmaceutical company’s stock after purchasing an additional 2,068 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in Gilead Sciences were worth $472,000 as of its most recent filing with the SEC.

    Other institutional investors and hedge funds also recently made changes to their positions in the company. Legacy Bridge LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at $30,000. Concord Wealth Partners bought a new stake in Gilead Sciences in the 4th quarter worth $33,000. Hanseatic Management Services Inc. bought a new stake in Gilead Sciences in the 4th quarter worth $37,000. EWG Elevate Inc. bought a new stake in Gilead Sciences in the 4th quarter worth $45,000. Finally, Duncker Streett & Co. Inc. grew its holdings in Gilead Sciences by 266.7% in the 4th quarter. Duncker Streett & Co. Inc. now owns 550 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 78.72% of the company’s stock.

    Insiders Place Their Bets

    In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the company’s stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $78.99, for a total value of $483,892.74. Following the completion of the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,539,568.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

    Gilead Sciences Stock Performance

    Shares of GILD stock opened at $78.52 on Friday. The company has a 50 day moving average price of $81.47 and a 200-day moving average price of $82.60. Gilead Sciences, Inc. has a 52 week low of $57.17 and a 52 week high of $89.74. The firm has a market capitalization of $98.06 billion, a PE ratio of 17.72, a P/E/G ratio of 0.91 and a beta of 0.38. The company has a quick ratio of 1.08, a current ratio of 1.37 and a debt-to-equity ratio of 1.14.

    Gilead Sciences (NASDAQ:GILD – Get Rating) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.26). The business had revenue of $6.35 billion for the quarter, compared to the consensus estimate of $6.33 billion. Gilead Sciences had a net margin of 20.65% and a return on equity of 39.35%. The business’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.12 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 6.75 earnings per share for the current year.

    Gilead Sciences Announces Dividend

    The company also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Shareholders of record on Thursday, June 15th will be given a $0.75 dividend. The ex-dividend date of this dividend is Wednesday, June 14th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.82%. Gilead Sciences’s payout ratio is currently 67.72%.

    Analyst Upgrades and Downgrades

    A number of equities research analysts have issued reports on the stock. Mizuho raised their price target on shares of Gilead Sciences from $88.00 to $101.00 and gave the stock a “buy” rating in a report on Tuesday, February 14th. Barclays lifted their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 18th. Morgan Stanley lifted their target price on shares of Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 12th. Piper Sandler lifted their target price on shares of Gilead Sciences from $111.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, February 3rd. Finally, StockNews.com initiated coverage on shares of Gilead Sciences in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.60.

    Gilead Sciences Company Profile

    (Get Rating)

    Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

    See Also

    Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating).

    Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

    Receive News & Ratings for Gilead Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Apple, Amazon, Alphabet, Ford, Nordstrom, and More Stock Market Movers

    Apple, Amazon, Alphabet, Ford, Nordstrom, and More Stock Market Movers

    [ad_1]

    This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

    https://www.barrons.com/articles/stock-market-movers-apple-amazon-google-ford-51675354870

    • Order Reprints
    • Print Article

    [ad_2]

    Source link

  • Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

    Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

    [ad_1]

    Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon.

    With reality setting in, it’s a buyer’s market for companies looking for acquisitions and partnerships, according to many of the pharmaceutical and medical technology executives who gathered at this year’s


    J.P. Morgan


    healthcare investor conference, which wrapped up in San Francisco on Thursday.

    [ad_2]

    Source link

  • WHO panel says no evidence yet that new omicron subvariants are more dangerous than others that are circulating

    WHO panel says no evidence yet that new omicron subvariants are more dangerous than others that are circulating

    [ad_1]

    The omicron sublineages named BQ.1 and XBB do not appear to have immune escape mutations that warrant being designated as variants of concern, a World Health Organization advisory panel said Friday.

    The decision will be reassessed regularly to ensure there is no change that might warrant a new designation, said the statement.

    As of Oct. 25, the XBB and XBB.1 lineages had been detected in 35 countries, according to a WHO weekly update from Thursday. The two are BA.2.10.1 and BA.2.75 recombinants, which were found in 26 countries in the previous week.

    “There has been a broad increase in prevalence of XBB in regional genomic surveillance, but it has not yet been consistently associated with an increase in new infections,” the panel wrote. However, early evidence does suggest a higher reinfection risk compared with other circulating omicron variants.

    BQ.1 is a sublineage of BA.5, which remains dominant globally, accounting for 77.1% of sequences forwarded to a centralized database in the week through Oct. 23. BQ.1 has been found in 65 countries.

    “While there are no data on severity or immune escape from studies in humans, BQ.1* is showing a significant growth advantage over other circulating Omicron sublineages in many settings, including Europe and the US, and therefore warrants close monitoring,” said the panel.

    The real risk of the variants depends on the level of immunity in a given region, it added. And with waning immune response from initial waves of omicron infection, and further evolution of omicron variants, “it is likely that reinfections may rise further,” said the statement.

    Read now: COVID-19 may be to blame for the surge in RSV illness among children. Here’s why.

    In the U.S., known cases of COVID are continuing to ease and now stand at their lowest level since mid-April, although the true tally is likely higher given how many people overall are testing at home, where the data are not being collected.

    The daily average for new cases stood at 37,412 on Thursday, according to a New York Times tracker, down 3% from two weeks ago. The daily average for hospitalizations was up 1% at 27,002, while the daily average for deaths is down 5% to 358. 

    Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

    Other COVID-19 news you should know about:

    • Gilead Sciences Inc.
    GILD,
    +12.92%
    said sales of its COVID treatment Veklury, formerly known as remdesivir, fell 52% to $925 million in the third quarter, driven by lower rates of COVID-19-related hospitalizations compared to the third quarter of 2021.” Last month, Gilead said the World Health Organization expanded its guidance to recommend remdesivir for treatment of patients with severe symptoms.

    • The pandemic devastated poor children’s well-being, not just by closing their schools, but also by taking away their parents’ jobs, sickening their families and teachers, and adding chaos and fear to their daily lives, the Associated Press reported, citing an analysis of test scores that was shared on an exclusive basis. The analysis found the average student lost more than half a school year of learning in math and nearly a quarter of a school year in reading—with some district averages slipping by more than double those amounts, or worse. Online learning played a major role, but students lost significant ground even where they returned quickly to schoolhouses, especially in math scores in low-income communities.

    • Optimism among U.S. companies in China has hit record low levels, an annual survey showed on Friday, as competitive, economic, and regulatory challenges compound the stresses already imposed by Beijing’s ongoing zero-COVID policies, Reuters reported. Just 55% of 307 companies surveyed by the American Chamber of Commerce in Shanghai and consulting firm PwC China described themselves as optimistic about the five-year business outlook. The reading is the lowest in the survey’s 23-year history and worse than in 2020, when COVID first surfaced, and during the trade standoff between Beijing and Washington in 2019.

    • The Chinese city of Shanghai has ordered mass testing on all 1.3 million residents of its downtown Yangpu district and is confining them to their homes at least until results are known, the AP reported. The demand is an echo of measures ordered over the summer that led to a two-month lockdown of the entire city of 25 million that devastated the local economy, prompting food shortages and rare confrontations between residents and the authorities.

    Here’s what the numbers say:

    The global tally of confirmed cases of COVID-19 topped 629.6 million on Friday, while the death toll rose above 6.58 million, according to data aggregated by Johns Hopkins University.

    The U.S. leads the world with 97.4 million cases and 1,070,064fatalities.

    The Centers for Disease Control and Prevention’s tracker shows that 226.9 million people living in the U.S., equal to 68.4% of the total population, are fully vaccinated, meaning they have had their primary shots.

    So far, just 22.8 million Americans have had the updated COVID booster that targets the original virus and the omicron variants, equal to 7.3% of the overall population.

    [ad_2]

    Source link